Chemo After Stroke: Is It Safe?

Chemotherapy is a treatment option for cancer that can increase the risk of stroke. However, the increased risk of stroke in cancer patients who receive chemotherapy is due to advanced cancer stage, and chemotherapy is not associated with the increased risk of stroke.

Chemotherapy can lead to stroke via endothelial toxicity and abnormalities in coagulation and hemostasis factors

Chemotherapy is a common treatment for cancer, but it can have some serious side effects, including an increased risk of stroke. This risk is generally quite low, but certain chemotherapy regimens are associated with a higher risk of stroke. For example, methotrexate (MTX), 5-fluorouracil, cisplatin, and L-asparaginase are all linked to a higher risk of chemotherapy-induced stroke. L-asparaginase, in particular, is well-known for its association with thrombosis and stroke.

The link between chemotherapy and stroke can be explained by the impact of chemotherapy on the vascular system. Chemotherapy can lead to endothelial toxicity, which is damage to the endothelial cells that line the blood vessels. This damage can increase susceptibility to pro-thrombotic phenotypes, which are characterised by an increased tendency for blood clot formation. Endothelial toxicity can also lead to vascular stiffness and cardiac dysfunction, which can contribute to heart failure.

In addition to endothelial toxicity, chemotherapy can also cause abnormalities in coagulation and hemostasis factors. Coagulation is the process of blood clot formation, and hemostasis is the process of stopping blood flow from a broken vessel. Abnormalities in these processes can increase the risk of stroke, as they can lead to the formation of blood clots in the cerebral arteries or veins. This can result in a reduction in blood flow and oxygen supply to the brain, causing a stroke.

Furthermore, chemotherapy can also increase the risk of stroke indirectly by increasing the patient's susceptibility to infections. Cancer treatments, including chemotherapy, can cause immunosuppression, which makes it easier for opportunistic infections to take hold. These infections can then trigger the manifestation of a stroke. Balancing the need for effective cancer treatment with the risk of treatment-related complications, such as stroke, can be challenging for oncologists.

Chemotherapy can trigger the manifestation of a stroke by transferring susceptibility via immunosuppression and the increase in opportunistic infections

Chemotherapy can lead to stroke via endothelial toxicity and abnormalities in coagulation and hemostasis factors. It can also trigger the manifestation of a stroke by transferring susceptibility via immunosuppression and the increase in opportunistic infections. In general, the risk of a chemotherapy-induced stroke is rather low and the risk is higher for some specific regimens, such as methotrexate (MTX), 5-fluorouracil, cisplatin and L-asparaginase. However, even neoadjuvant chemotherapy (NC) has been linked to an increased risk of stroke; Abt et al (2014) reported that NC was linked to a higher risk of short-term stroke and mortality in patients undergoing brain tumor resection.

The risk of a chemotherapy-induced stroke is rather low and the risk is higher for some specific regimens, such as methotrexate, 5-fluorouracil, cisplatin and L-asparaginase

The risk of a chemotherapy-induced stroke is rather low, but it is higher for some specific regimens, such as methotrexate, 5-fluorouracil, cisplatin, and L-asparaginase.

Chemotherapy can lead to stroke via direct tumour effects, hypercoagulability, infections and the effects of the cancer-treatment, chemo- and radiotherapy

Chemotherapy can lead to stroke via several mechanisms, including direct tumour effects, hypercoagulability, infections and the effects of the cancer-treatment, chemo- and radiotherapy.

Chemotherapy has often been blamed as the cause of cerebral arterial or venous thrombosis, although this can occur in the setting of advanced malignancy as well

Chemotherapy has been blamed for causing cerebral arterial or venous thrombosis, which can lead to a stroke. However, this risk is generally low, and the cause of the stroke may be due to the cancer itself or other factors. The relationship between chemotherapy and stroke is complex and requires careful consideration.

Several studies have found a link between chemotherapy and an increased risk of thrombosis, particularly venous thromboembolic events (VTEs). For example, Khorana et al. found that cancer patients who received chemotherapy had significantly higher VTE rates in the 12 months following treatment initiation compared to non-cancer patients. This risk may be due to direct drug-induced damage to the endothelium, increased expression of TF procoagulant activity, and hepatotoxicity, leading to a decrease in natural anticoagulant proteins. Additionally, some chemotherapeutic agents, such as platinum-based agents (cisplatin), vascular endothelial growth factor (VEGF) inhibitors, and L-asparaginase, have been specifically associated with an increased risk of thrombosis and stroke.

On the other hand, it is important to recognize that cancer itself can heavily influence the occurrence of strokes. Cancer-mediated hypercoagulability, coagulation disorders, infections, and cancer treatments can all contribute to the risk of stroke in cancer patients. In some cases, the underlying cancer may be the primary driver of thromboembolic events. Therefore, reducing cancer activity through directed cancer treatments, such as cytoreductive and targeted chemotherapy, is crucial in managing this risk.

The decision to prescribe chemotherapy after a stroke is challenging. Oncologists may be hesitant due to concerns about the patient's ability to tolerate the side effects and the potential for the treatment to trigger another stroke. However, chemotherapy can be beneficial in treating the underlying cancer and reducing the risk of further thromboembolic events. A careful assessment of the risks and benefits is necessary to determine the most appropriate course of action for each individual patient.

In conclusion, while chemotherapy has been implicated in causing cerebral arterial or venous thrombosis and increasing the risk of stroke, it is important to consider other factors, such as the type of cancer, the presence of coagulation disorders or infections, and the specific chemotherapeutic agents used. The complex relationship between cancer, chemotherapy, and stroke requires a personalized approach to treatment and management, taking into account the unique circumstances of each patient.

Frequently asked questions